Corporate venture groups are poised to become one of the main sources of funding for early-stage biotechs thanks to the current economic climate. Even if corporate venture groups invest at the same levels as previous years, some industry veterans believe they could play a role in up to half of the early-stage financings this year, largely because the traditional sources of financing--the public market and venture capital groups flush with cash--have disappeared. And the new vigor of corporate venture offers big benefits to both small biotechs and Big Pharma.
In the current biotech economy, corporate venture groups are playing an increasingly important role in the funding of early-stage start-ups. As their cachet grows, these outfits can drive harder bargains, including option-style deals aligned with their parent companies’ business development interests.
Hit hard by the current economy, traditional VCs are increasingly reliant on pharmaceutical companies as their sole means of providing...